858 Therapeutics

858 Therapeutics is a biotechnology company focused on discovering small molecule therapeutics for novel targets in oncology and immunology. The company emphasizes innovative approaches in synthetic lethality, innate immunity, and RNA modulation. Its lead program is a PARG inhibitor currently in early clinical development.